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Summary. The bactericidal activity of two new 4-quinolones, DU-6859a and DV-775 la, 
was investigated against strains of Escherichia coli, Staphylococcus aureus, S. epidermidis, 
Streptococcus pneumoniae and Enterococcus faecalis. DU-6859a and DV-775 1 a were more 
bactericidal than any 4-quinolone tested previously. Furthermore, DU-6859a was unique 
among 4-quinolones in being able to kill Ent. faecalis after incubation for only 3 h in nutrient 
broth. The bactericidal mechanisms of DV-755 1 a were similar to those of other 4-quinolones, 
but, uniquely, DU-6859a possessed additional bactericidal mechanisms against both Str. 
pneumoniae and Ent. faecalis. This may explain the unusually potent bactericidal activity of 
this agent against these species. These results show that DU-6859a is a unique extended- 
spectrum 4-quinolone, which should prove to be superior to established 4-quinolones. 
Introduction 
Preliminary studies have suggested that DU-6859a 
and DV-7751a may be significantly more active than 
currently available 4-quinolones against a wide range 
of bacteria.', To investigate this claim further, their 
bactericidal activity was studied against strains of 
Escherichia coli, Staphylococcus aureus, S. epidermidis, 
Streptococcus pneumoniae and Enterococcus faecalis. 
The bactericidal activity of 4-quinolones has been 
described with respect to three mechanisms of action, 
termed A, B and C. Mechanism A requires the bacteria 
to be undergoing multiplication and protein or RNA 
synthesis. It occurs with all 4-quinolones, except when 
high concentrations are used against Pseudomonas 
ae~uginosa,~ and is the sole bactericidal mechanism of 
older 4-quinolones, such as nalidixic and oxolinic 
acids.* Mechanism B is an additional mechanism 
of several modern 4-quinolones including ofloxacin, 
ciprofl~xacin,~ lomefloxacin,6 levofloxacin,' fleroxa- 
cin, pefloxacin,* PD13 16289 and sparfloxacin.lO Unlike 
mechanism A, mechanism B allows bactericidal 
activity against non-dividing bacteria and does not 
require active protein or RNA ~ynthesis.~ A related 
bactericidal mechanism, termed B,, has been identified 
with clinafloxacin (PD127,391.)" Although it does 
not require active protein or RNA synthesis, mech- 
anism B,, is nevertheless lost against non-dividing 
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bacteria.ll Mechanism C, which has so far been found 
only with norfloxacin12 and enoxacin,6 does not 
require bacterial multiplication, but does need active 
protein and RNA synthesis. 
Possession of additional mechanisms against one 
bacterial species does not guarantee their occurrence 
against others. For example, ciprofloxacin has mech- 
anism B against E. C O Z ~ , ~  but possesses only mechanism 
A against staphylococ~i.~~ Ofloxacin, on the other 
hand, exerts mechanism B against both E. coli and 
staphyloc~cci,~. l3 as does levofloxacin.' All 4- 
quinolones tested so far possess only bactericidal 
mechanism A against Str. pneumoniael* and Ent. 
faecalis,15 and these species represent a considerable 
weakness in the bactericidal spectrum of 4-quinolones. 
This is especially pertinent for Ent. faecalis, for which 
the rate of bactericidal activity of 4-quinolones is 
slower than for other gram-positive b a ~ t e r i a . ~ ~  l5  This 
study aimed to characterise the bactericidal 
mechanisms of DU-6859a and DV-7751a and to 
determine if they had any advantage over earlier 
agents against pneumococci and enterococci. 
Materials and methods 
Bacterial strains 
E.  coli KL16,16 S .  epidermidis SK360,13 S. aureus 
E3T,17 Str. pneumoniae C3LN41s and Ent. faecalis 
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ATCC 1943315 were used. These species and strains 
were chosen because of their previous use in 
determining the bactericidal activity and mechanisms 
of action of other 4-quinolones. 
An tibacterial agents 
DU-6859a and DV-775 1 a (Daiichi Pharmaceutical 
Co., Japan) were initially dissolved in 0.1 M NaOH at 
10 mg/ml and immediately diluted with sterile distilled 
water. Chloramphenicol (Parke-Davis, Pontypool, 
Gwent) was prepared initially in methanol and diluted 
further in sterile distilled water. 
Determination of the bactericidal activities of 
DU-68.59~ and DV-7751a 
Ten ml of Nutrient Broth No. 2 (Unipath 
Basingstoke, Hants) was inoculated with bacteria and 
then incubated overnight at 37°C to provide organisms 
for study. For Str. pneumoniae cultures, the nutrient 
broth was supplemented with laked horse blood 
(Unipath) 7 YO. 
To study bactericidal activity, sterile double- 
strength nutrient broth first was dispensed in 5-ml 
volumes in sterile 1 oz bottles. The aqueous 4- 
quinolone and sterile distilled water were then added 
to give a final volume of 9.8 ml, and a drug con- 
centration between 0.01 5 and 90 mg/l. When Str. 
pneumoniae was tested, laked horse blood was added 
to a final concentration of 7%. When required, 
aqueous chloramphenicol was also added to a final 
concentration of 20 mg/l or 2.5 mg/l for Str. 
pneumoniae. These concentrations of chloramphenicol 
were bacteriostatic (data not shown). The bottles were 
then warmed for at least 15 min in a waterbath at 
37"C, after which 0.2 ml of overnight culture, con- 
taining c. 2.5 x lo8 cfu/ml, was added. Viable counts 
at time zero thus were c. 5 x lo6 cfu/ml. 
In some experiments PBS (NaC1 0.9% in 0.025 M 
sodium phosphate buffer, pH 7.4), replaced nutrient 
broth. In these cases the overnight cultures used were 
harvested by centrifugation at 4000 rpm for 15 min, 
washed, and then resuspended in 10 ml of sterile PBS 
to prevent nutrient carry-over. To prevent autolysis of 
Str. pneumoniae, horse serum (Unipath) 7% was 
added when this organism was studied. 
All incubations were for 3 h at 37"C, except that 
Ent. faecaZis cultures also were incubated for 6 and 
24 h. Experiments were stopped by adding 10 ml of 
sterile ice-cold nutrient broth, after which the cells 
were harvested by centrifugation at 4000 rpm for 
15 min, then resuspended in 10 ml of sterile nutrient 
broth at room temperature to prevent drug carry-over. 
Viable counts were determined by serial dilution in 
sterile nutrient broth at room temperature, and 0. 1-ml 
amounts of the dilutions were spread on nutrient agar, 
supplemented with laked horse blood 7% for Str. 
pneumoniae. Owing to the strong bactericidal activity 
of DU-6859a against E. coli, a total volume of 1 ml 
was spread in three samples of 0.3 ml and one of 0.1 ml 
when this agent was tested at concentrations between 
0.5 and 3 mg/l. All plates were incubated for 2 days at 
37°C before the colonies were counted. 
Results 
A biphasic dose response occurred with DU-6859a 
against E. coli, with an optimum bactericidal con- 
centration (OBC) of 0.9 mg/l (fig. 1). Most killing 
occurred in normal nutrient broth culture, but con- 
siderable killing was still achieved when a bacterio- 
static concentration of the protein synthesis inhibitor 
chloramphenicol was added or when the bacteria 
were resuspended in PBS prior to exposure to the 
quinolone. Similar behaviour was seen for DV-775 1 a 
against E. coZi and for both DU-6859a or DV-7751a 
against S. aureus or S.  epidermidis (not shown). 
The proportions of E. coZi, S.  aureus, S.  epidermidis 
and Str. pneumoniae cells that survived exposure to 
DU-6859a or DV-7751a at OBC are shown in the 
table. Both drugs had OBCs of 0-9 mg/l for E. coli, 
but DV-7751a had lower OBCs than DU-6859a for 
staphylococci. The extent of killing by either DU- 
6859a or DV-7751a at OBC in nutrient broth was 
greater than with any 4-quinolone studied pre- 
viously. In nutrient broth, DU-6859a was 58 times 
more bactericidal than DV-7751a against E. coli 
and 19 times more so against S. epidermidis, but 
both 4-quinolones had approximately equal bacteri- 
cidal activity at OBC against S. aureus. However, 
DU-6859a was more bactericidal than DV-775 l a  
against all three of these species in nutrient broth 
containing chloramphenicol, or in PBS. 
DV-7751a was most bactericidal against Str. 
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Fig. 1. Survival of E. coli KL16 after exposure to DU-6859a for 3 h 
in nutrient broth (a), phosphate-buffered saline (0) or nutrient 
broth containing chloramphenicol 20 mg/l (m) at 37°C. 
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Table. Survival rates of bacteria exposed to DU-6859a or DV-775 la at OBC for 3 h 
at 37°C 
4-Quinolone Organism 
(OBC, mg/l) 
nutrient 
broth* plus PBSt nutrient 
broth* chloramphenicol 
DU-6859a E.  coli (0.9) 
S .  aureus (3.0) 
S.  epidermidis (3.0) 
Str. pneumoniae (0-9) 
E. coli (0-9) 
S.  aureus (0.9) 
S.  epidermidis (1 ' 5 )  
Str. pneumoniae (1.5) 
DV-775 1 a 
0.00045 
0.0043 
0.00 1 3 
0.09 5 
0026 
0.0046 
0.025 
0.17 
*For Str. pneumoniae laked horse blood 7 O/O was added. 
+For Str. pneumoniae horse serum 7% was added. 
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Fig. 2. Survival of Str. pneumoniae C3LN4 after exposure to: a, DV-7751a or b, DU-6859a for 3 h in nutrient broth (a), phosphate-buffered 
saline (0) or nutrient broth containing chloramphenicol 2.5 mg/l (B) at 37°C. 
pneumoniae in blood broth and was less so when a 
bacteriostatic concentration of chloramphenicol was 
added, or when tested in PBS plus horse serum 7 %. 
Nevertheless, some killing did occur under these latter 
conditions (fig. 2a). In contrast, DU-6859a was equally 
potent against pneumococci in blood broth whether or 
not chloramphenicol was added (fig. 2b), and was only 
slightly less bactericidal in PBS plus horse serum. This 
strong bactericidal activity of DU-6859a against non- 
dividing Str. pneumoniae is unique among 4-quinolone 
antibacterial agents. 
Weak bactericidal activity was seen for DV-7751a 
against Ent. faecalis after incubation for 3 h in nutrient 
broth at 37"C, but more significant killing was seen 
only after incubation for 6 or 24 h (fig. 3a). By contrast, 
DU-6859a had good bactericidal activity against this 
organism within 3 h in nutrient broth at 37°C (fig. 3b), 
although still more killing was observed after 6 or 24 h. 
This rapid bactericidal activity of DU-6859a against 
Ent. faecalis is also unique among 4-quinolones. When 
bactericidal activity was tested against non-dividing 
enterococci in PBS, no significant killing occurred with 
DV-775 la up to 90 mg/L, even after 24 h (fig. 4a), nor, 
during exposure periods shorter thafi 24 h, in nutrient 
broth containing chloramphenicol. DU-6859a did not 
kill Ent. fueculis in PBS even after 24 h (fig. 4b); but, 
unlike with DV-7751a, bactericidal activity was seen in 
nutrient broth containing chloramphenicol, with 10, 1 
and 0.01 % survivors remaining after incubation for 
3, 6 and 24 h, respectively. These results show that 
DU-6859a, unlike DV-775 la, possessed another 
bactericidal mechanism, in addition to mechanism A, 
against Ent. faecalis, and may explain the compound's 
rapid bactericidal rate against this species. 
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Fig. 4. Survival of En?. faecah ATCC 19433 after exposure to : a DV-7751a or b, DU-6859a for 24 h in phosphate-buffered saline (O), or 3 h 
(a), 6 h (M) or 24 h (A) in nutrient broth containing chloramphenicol20 mg/l at 37°C. 
Discussion DV-7751a had very similar OBCs against E. coli, S.  
aureus and S. epidermidis. This is unusual among 4- 
quinolones, and has only been seen previously with 
sparfIoxacin.lo DU-6859a, on the other hand, was 
more like other 4-quinolones in that its OBC for 
E. coli was about three-fold lower than for either 
staphylococcal species. However, comparison of OBCs 
alone may not allow a fair assessment of DV-7751a 
and DU-6859a because both drugs were extremely 
bactericidal at even lower concentrations. This was 
especially marked for DU-6859a against E. coli, where 
a modification of the usual viable counting method 
The bactericidal activity and mechanisms of many 
4-quinolones have been studied p rev iou~ ly .~ -~~  In this 
study, the bactericidal activities and mechanisms of 
action of two new 4-quinolones, DU-6859a and DV- 
775 la, were investigated against the same test strains 
used in these earlier studies. DV-7751a and DU-6859a, 
like many other 4-quinolones, displayed another bac- 
tericidal mechanism, in addition to mechanism A, 
against E. coli, S.  aureus and S. epidermidis. This 
appeared to be mechanism B, because both drugs 
could kill bacteria in the absence of active protein or was necessary to enumerate the few survivors. 
RNA synthesis and when the bacteria were not OBCs of both new quinolones against Str. 
multiplying. pneumoniae were considerably lower than those of 
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other 4-quinolones." Moreover, both DV-775 la  and 
DU-6859a were able to kill Str .  pneumoniae in the 
absence of active protein or RNA synthesis, or when 
the bacteria were not multiplying. indicating the 
presence of mechanism B. All 4-quinolones previously 
tested showed only mechanism A against this species.14 
The occurrence of mechanism B may explain the 
greater bactericidal activity of these drugs for 
pneumococci and may be extremely useful in the 
treatment of infections, where the bacteria may not be 
dividing. Mechanism B was particularly strong with 
DU-6859a- where essentially the same extent of killing 
was seen against Str. pneumoniae in blood broth 
whether or not a bacteriostatic concentration of 
chloramphenicol was added. Possession of such a 
powerful mechanism B suggests that DU-6859a might 
be used in combination with those antibacterial agents 
that inhibit bacterial protein synthesis, whereas the 
bactericidal activity of other 4-quinolones may be 
seriously impaired by inhibitors of protein synthesis, 
as has been shown with levoflo~acin.'~ Such com- 
bination therapy might be desirable to prevent the 
development of bacteria 1 resistance. 
Previous 4-quinolones have had very slow rates of 
bactericidal activity against Ent. faecalisg. l5  although, 
contrary to a recent claim,2o they are not merely 
bacteriostatic against these organisms. In this study 
a slow rate of bactericidal activity was seen with 
DV-775 la, although reasonable killing occurred after 
exposure for 6 h, whereas other 4-quinolones require 
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